High cost of chemotherapy for gynecologic malignancies

• Published in: Japanese journal of clinical oncology 2024-10, Vol.54 (10), p.1078-1083
• Main Authors: Takahashi, Nobutaka, Seki, Toshiyuki, Sasaki, Keita, Machida, Ryunosuke, Ishikawa, Mitsuya, Yunokawa, Mayu, Matsuoka, Ayumu, Kagabu, Masahiro, Yamaguchi, Satoshi, Hiranuma, Kengo, Ohnishi, Junki, Sato, Toyomi
• Format: Article
• Language: English
• Subjects: Antineoplastic Agents - economics; Antineoplastic Agents - therapeutic use; Antineoplastic Combined Chemotherapy Protocols - economics; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Bevacizumab - administration & dosage; Bevacizumab - economics; Bevacizumab - therapeutic use; Drug Costs - statistics & numerical data; Female; Genital Neoplasms, Female - drug therapy; Genital Neoplasms, Female - economics; Health Care Costs - statistics & numerical data; Humans; Japan; Ovarian Neoplasms - drug therapy; Ovarian Neoplasms - economics; Poly(ADP-ribose) Polymerase Inhibitors - economics; Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use; Surveys and Questionnaires; Uterine Cervical Neoplasms - drug therapy; Uterine Cervical Neoplasms - economics
• ISSN: 1465-3621; 1465-3621
• DOI: 10.1093/jjco/hyae089

The prognosis of gynecological malignancies has improved with the recent advent of molecularly targeted drugs and immune checkpoint inhibitors. However, these drugs are expensive and contribute to the increasing costs of medical care. The Japanese Clinical Oncology Group (JCOG) Health Economics Committee conducted a questionnaire survey of JCOG-affiliated facilities from July 2021 to June 2022 to assess the prevalence of high-cost regimens. A total of 57 affiliated facilities were surveyed regarding standard regimens for advanced ovarian and cervical cancers for gynecological malignancies. Responses were obtained from 39 facilities (68.4%) regarding ovarian cancer and 37 (64.9%) concerning cervical cancer, with respective case counts of 854 and 163. For ovarian cancer, 505 of 854 patients (59.1%) were treated with regimens that included PARP inhibitors, costing >500 000 Japanese yen monthly, while 111 patients (13.0%) received treatments that included bevacizumab, with costs exceeding 200 000 Japanese yen monthly. These costs are ~20 and ~10 times higher than those of the conventional regimens, respectively. For cervical cancer, 79 patients (48.4%) were treated with bevacizumab regimens costing >200 000 Japanese yen per month, ~10 times the cost of conventional treatments. In this survey, >70% of patients with ovarian cancer were treated with regimens that included poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitors or bevacizumab; ~50% of patients with cervical cancer were treated with regimens containing bevacizumab. These treatments were ~10 and ~20 times more expensive than conventional regimens, respectively. These findings can inform future health economics studies, particularly in assessing cost-effectiveness and related matters.